"R" stands for "Risk Rating." A "1" means I view the situation as having an extreme amount of risk. A "10" means very low risk -- a much sounder, more financially stable situation. You'll see hardly any with a "1" or "10" rating. I chose "10" to mean lowest risk so the higher the number after each of the three codes, the more favorable the rating.

"M" stands for "Midterm Appreciation Potential." A "1" means I view the situation as having a small degree of midterm ("mid-term" is six to 12 months) potential. A "10" means really outstanding midterm potential.

"L" stands for "Long-term Appreciation Potential." A "1" means I view the situation as having a small degree of long-term ("long-term" is over one year) potential. A "10" means really outstanding long-term potential.

ImmuNis Corp. (OTC Bulletin Board/IMMCE) owns interests & invests in developing health care products that address health problems in both developing countries & industrialized nations. Its interests may be in the form of strategic partnerships, direct ownership interests in patents, or the control of commercial or marketing rights.

IMMCE has a 25% interest in the commercial rights to DIAB II, an oral treatment for type II diabetes, for territories outside of oriental Asia -- 15 million Americans & more than 150 million people suffer from diabetes worldwide. The worldwide market for Type II diabetes treatment exceeds $10 billion annually -- the U.S. market for insulin sensitizers is expected to grow by more than 50% per year to $5.1 billion by the end of 2003. DIAB II is a potent member of a new class of anti-diabetic agents. It increases the patient's metabolic rate -- it increases energy & one's feeling of well-being. It improves the patient's ability to utilize both endogenous & injected insulin, the hormone that controls blood sugar levels.

IMMC utilizes an established market & has an improved product for the users of insulin sensitizers. Recently it announced that Biotech Holdings Ltd.'s (the Canadian-based pharmaceutical company that controls the worldwide manufacturing & marketing rights to the drug) is near completion of an area in their facility that will manufacture & deliver DIAB II. Delivery is postured for 2000. IMMC is already operating with no debt & the returns from future sales of DIAB II could be impactive to IMMC's bottom line.

Distribution agreements have been signed in South America with firms in Brazil, Chile, Peru, Venezuela, & Argentina. DIAB II must go through the approval process in each country, so keep in mind that positive cash flow will not occur until that process is completed. In a clinical trial performed by an independent Brazilian medical laboratory, I was told it produced diabetic control with HbA1c reduced to 5.85% (a normal level for non-diabetics), with no laboratory or clinical toxicity, & with weight loss, not weight gain. DIAB II is the only insulin sensitizer showing all three of these important characteristics. As I write this (12/28/99 @ 10:28 a.m.) IMMCE is trading at 1. Call John King @ 805-446-1189, fax 805-446-0080. [R-5; M-6; L-8]

Globus Wireless, Ltd. (OTC Bulletin Board/GBCL) changed its name 12/15/99 from Globus Technologies Ltd. because of its market opportunities in the wireless communications field. GBCL is in research, design, manufacture, marketing, & distribution of wireless products. Its initial patented product is called the MegaRangeTM Antenna. It enhances the operational efficiency of wireless phones.

The antenna has the ability to increase range, lower battery consumption, reduce dropped calls, & increase voice clarity. Its most important advantage is that it lowers radiation to the cell phone user.

You may have seen the recent press about the risk of radiation from cell phones. Since the antenna is usually adjacent to one's head, a lot of the energy is radiated to one's brain. Physicians & scientists are worried about the long-term effects of such radiation on the brains of people who use their cell phones a lot.

The MegaRangeTM Antenna is designed so that the greatest amount of radiation is up & away from the head. SAR (Specific Absorption Rate) scans of the heads of users show regular cell phones produce high amounts of radiation in the brain, whereas cell phones equipped with GBCL's antenna show almost a complete lack of such radiation in the brain.

Moving the point of highest radiation away from the user fortunately has not adversely affected the far-field radiation performance of the phone -- it equals the 360 degree far-field performance of leading antenna products.

GBCL on 12/9/99 announced its development & marketing partnership with AudenTechnology Mfg. Co., Ltd. of Pa-Te City, Taiwan, R.O.C. to develop & market a patented ceramic embedded antenna technology to OEMs that create products for the fast growing wireless data devices market. That includes notebook computers, PDAs (Personal Data Assistants), & palm-held organizers as consumers demand wireless access to the Internet. Auden has manufactured antennas since 1981. This is a good combination -- Auden's manufacturing expertise & facilities, & GBCL's patented technology.

As you may be aware, wireless communication is one of the fastest market growing segments today. I like this situation because it addresses a very worrisome aspect of this growing trend. GBCL on 12/28/99 is trading at 1-3/4. Call Deborah Bayne at Vantage Point Capital @ 800-580-4382, fax 905-631-7854. www. globuscellular.com [R-5; M-7; L-8]

Update Briefs

This section does not include information from all the news releases I receive on situations I have covered in past Recommen-dations or Sneak Previews. If you hold such stocks, please go to

...continued on next page, click here

Disclaimer: The public companies featured in the Corporate Profiles listed in the "Special Situation" section on the Home Page of www.WallStreetCorner.com are our regular clients. Each such client pays an annual cash fee of $12,000, or alternatively, a monthly cash fee of $495 plus a negotiated number of Form 144 restricted shares for our service. We on rare occasions accept free-trading shares, but we usually hold such shares for the long pull - we do not engage in trading. Such fees are disclosed as part of the Corporate Profile prepared and posted on the particular company involved. The basic coverage provided to such clients primarily includes the preparation of their Corporate Profile, posting it here at WallStreetCorner.com, and the distribution of email alerts to our international database of investors and financial professionals when their Profile is initially posted, and each time their Profile is subsequently updated. We expect our clients to work with us in a team effort by calling us each time they have achieved a significant milestone. We then update their Profile and issue an additional email alert to our totally opt-in email database (as of July 2008, members of that database are from over 96 countries). The email distributions we make are a key element of our service -- those, as well as the updated Corporate Profile are what together are designed to achieve a gradual buildup of new shareholders who generally hold for the long term. If you are an officer at a public company and want the exposure afforded at WallStreetCorner.com, email Larry at up415@aol.com or call him at 843-645-2729. Information displayed by WallStreetCorner in its Corporate Profiles, and in its editorial or other columns, does not constitute an offer to buy, sell, or trade a security of any kind, including stock. Larry Oakley, and/or WallStreetCorner.com, Inc., does not recommend that any person, institution, or other entity make any decisions or form any opinions, etc. based on the information on this site. All visitors to this site are urged to do two things before investing in any stock: (1) Call the company and ask questions -- if there is anything you do not like regarding such call, pass -- our goal is to bring you a selection of what we feel are growth situations with good long-term appreciation potential, but you must accept the responsibility of making your own decisions regarding which situations to invest in -- do not give up that responsibility; and (2) Consult a qualified financial professional before taking any actions in regards to buying, selling, or trading securities (stocks or other forms of equity). Companies covered in Conservative Speculator, a newsletter accessed from WallStreetCorner, or in any of Larry Oakley's other editorial venues ("Opinion," "Stock Pick," "Comment," and "Bold Ventures" columns, and in any other editorial venue to which Larry contributes) do not pay for such editorial coverage; the companies Larry covers editorially have never, do not now, and never will be charged for editorial coverage. The only paid portions of WallStreetCorner.com are the Profiles and email distributions (email distributions are a part of the client's package, but occasionally are paid for separately by non-clients - if a non-client wants to utilize our email distributions, the cost is $2,000 for the first distribution, $1,500 for the second, $1,000 for the third, and $500 for all subsequent distributions made for the same company). On occasion, Larry Oakley shares his opinion regarding a private company or its product or service. Bear in mind that nothing at that special section is an investment possibility. To see that section, click where on the home page it says: "Click here to access our Special Emerging Growth Situations." See the introductory portion of that special section for additional information regarding the material covered there.

WallStreetCorner.com
WallStreetCorner.com, Inc.